Table 2.
Follow-up and outcome data. Data are presented as n (%) and median (IQR: 25th–75th percentile).
| COVID-19 | Controls | |||||
|---|---|---|---|---|---|---|
| Normonatremia | Hyponatremia | Hypernatremia | Normonatremia | Hyponatremia | Hypernatremia | |
| Patients, n | 116 | 50 | 5 | 677 | 149 | 18 |
| Follow-up data | ||||||
| Length of hospital stay (days) | 0 (0– 5) | 7 (5–12) | 10 (6–22) | 0 (0–5) | 5 (0–9) | 2 (1–10) |
| Deaths within 30 days | 3 (3) | 5 (10) | 4 (80) | 24 (4) | 5 (3) | 3 (17) |
| Time to death (days) | 4 (2.5–6) | 7 (6–9) | 14 (4.5–22.5) | 8 (2–25) | 27 (13–29) | 1 (1–4.5) |
| 30-day rehospitalization | 8 (7) | 5 (10) | 0 (0) | 57 (8) | 22 (15) | 4 (22) |
| ICU admission, | 18 (16) | 14 (28) | 4 (80) | 20 (3) | 14 (9) | 3 (17) |
| Intubation need, | 14 (12) | 9 (18) | 3 (60) | 10 (1) | 9 (6) | 1 (6) |
| i.v. Norepinephrine | 13 (11) | 9 (18) | 2 (40) | 8 (1) | 8 (5) | 2 (11) |
| ARDS | 10 (9) | 9 (18) | 3 (60) | 4 (1) | 2 (1) | 0 (0) |
ARDS, acute respiratory distress syndrome.